A retrospective analysis of Selective Internal Radiation Therapy (SIRT) and chemotherapy for metastatic pancreatic adenocarcinoma
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related deaths in Australia, with a 5-year survival rate of less than 13%. The liver is the most common site of PDAC metastasis, and is observed in over 50% of cases. Standard chemotherapy, including regimens such as FOLFIRINOX or nab-paclitaxel plus gemcitabine, offer limited survival benefits, with median survival rates typically below one year. Selective internal radiation therapy (SIRT) with Yttrium-90 (90Y) microspheres is used to target liver metastases, but the optimal chemotherapy companion for SIRT in metastatic PDAC remains unknown. METHODS: We conducted a retrospective audit of 32 patients with metastatic PDAC treated with SIRT and chemotherapy, and evaluated the clinical outcomes associated with platinum-based versus non-platinum-based regimens. RESULTS: Patients who received platinum-based chemotherapy alongside SIRT had a median PFS of 10 months, compared to 2 months in those treated with non-platinum-based regimens. Stratified analysis revealed that patients receiving platinum-based chemotherapy in the first-line setting achieved a median post-SIRT survival of 16 months, compared to 4 months for those treated in later lines. For non-platinum-based regimens, median post-SIRT survival was 9 months in the first-line and 6 months in later lines. Median OS from Stage IV diagnosis was 17 months for patients with liver-only metastases and 15 months for those with additional extra-hepatic disease, suggesting that liver disease burden remains a dominant driver of outcomes. CONCLUSIONS: These findings describe survival outcomes among patients treated with SIRT and chemotherapy for metastatic PDAC in a real-world setting. Longer observed survival was seen in patients who received platinum-based chemotherapy alongside SIRT, particularly in the first-line setting. Given the descriptive design and small sample size, these findings should be interpreted as hypothesis-generating and may inform future prospective evaluation of SIRT-chemotherapy combinations.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A retrospective analysis of Selective Internal Radiation Therapy (SIRT) and chemotherapy for metastatic pancreatic adenocarcinoma
- Date Crossref
- 06/05/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Epworth Hospital pays non établi dans la noticeÉtablissement de santé
-
The University of Melbourne Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
St Vincent’s Private Hospital Sydney pays non établi dans la noticeÉtablissement de santé
-
Eastern Health pays non établi dans la noticeÉtablissement de santé
-
Box Hill Hospital pays non établi dans la noticeÉtablissement de santé
-
St Vincent's Hospital Melbourne pays non établi dans la noticeÉtablissement de santé
-
Austin Health pays non établi dans la noticeÉtablissement de santé
-
The Jreissati Pancreatic Centre at Epworth pays non établi dans la noticeInstitution
-
Knox Private Hospital pays non établi dans la noticeÉtablissement de santé
-
I-MED Radiology pays non établi dans la noticeInstitution
-
St. Vincent's Hospital pays non établi dans la noticeÉtablissement de santé
-
Monash University pays non établi dans la noticeUniversité ou école supérieure
Epworth Hospital, Department of Surgery — The University of Melbourne et St Vincent’s Private Hospital Sydney, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.